生物標記的全球市場:2022-2028年
市場調查報告書
商品編碼
1123230

生物標記的全球市場:2022-2028年

Global Biomarker Market Research and Forecast 2022-2028

出版日期: | 出版商: Orion Market Research | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

全球生物標記的市場規模在預測期間內預計顯示14.6%的年複合成長率。

慢性疾病的高盛行率,診斷用途的生物標記採用增加,政府對癌症研究及臨床試驗的高資金援助,藥物研發及開發的應用增加等要素促進該市場的成長。還有對R&D的政府舉措增加,數位生物標記等的新技術,個人化醫療的採用增加也預計產生對市場有利的機會。

本報告提供全球生物標記的市場調查,市場概要,市場成長的各種影響因素分析,市場規模的變化、預測,各種區分、各地區/主要國家的明細,競爭環境,主要企業簡介等彙整資訊。

目錄

第1章 報告概要

第2章 市場概要、洞察

第3章 競爭情形

  • 主要企業分析
  • 主要策略分析
  • COVID-19主要企業的影響

第4章 市場決策要素

  • 推動要素
  • 阻礙因素
  • 機會

第5章 市場分析:各種類

  • 全球生物標記市場:各類型
    • 基因生物標誌物
    • 蛋白質生物標記
  • 全球生物標記市場:各用途
    • 藥物研發、開發
    • 診斷
    • 預後
    • 預測
    • 其他(風險評估)
  • 全球生物標記市場:各疾病
    • 癌症
    • 心臟
    • 腎臟
    • 中樞神經系統疾病
    • 其他(Nash)
  • 全球生物標記市場:各終端用戶
    • 醫院
    • 診斷中心
    • 研究機關

第6章 地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 企業簡介

  • Abbott Laboratories
  • ACS Biomarker B.V.
  • Agilent technologies inc.
  • Abcodia Ltd.
  • Adx Neurosciences
  • Avacta Life Sciences Ltd.
  • Agendia Inc.
  • Astellas Pharma Inc.
  • Angle plc
  • Almac Group
Product Code: OMR2018374

Global Biomarker Market Size, Share & Trends Analysis Report by Type (Genomic Biomarker, and Protein Biomarker) By Application (Drug Discovery & Development, Diagnostic, Prognostic, Predictive, and Others ) By Disease (Cancer, Cardiac, Renal, Central Nervous System Disease, and Others) By End-User (Hospitals, Diagnostic Centre, and Research Institute) Forecast 2021-2027

The global market for a biomarker is projected to have a CAGR of 14.6% during the forecast period. A biomarker is an objective measure that captures what is happening in a cell or an organism at a given moment. Biomarkers can serve as early warning systems for health. Biomarkers can have molecular, histologic, radiographic, or physiological characteristics. The use of biomarkers in basic and clinical research as well as in clinical practice has become so commonplace that their presence as primary endpoints in clinical trials is now accepted almost without question. The key factors contributing to the growth of the global biomarker market include the high prevalence of chronic diseases, rising adoption of the biomarker for diagnostic applications, high government funding for cancer research and clinical trials, increasing application in drug discovery and development. According to the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) report, 6 in 10 adults in America live with at least one chronic disease, and 4 in 10 adults are with two or more. It is estimated that by 2060, the U.S. population aged 65 years and older will more than double, from 46 million today to 98 million. The high prevalence of chronic disease led to the demand for an effective biomarker which, in turn, further drive the market growth. The increase in the number of Contract Research Organizations (CROs) and the low cost of clinical trials in emerging economies are anticipated to further boost the growth of the market.

However, the high investments cost and low-cost benefit ratio and technical issues such as sample collection and storage are restraining the growth of the biomarker market. The increasing government initiatives for R&D, the introduction of new technologies such as digital biomarker and rising adoption in personalized medicine are expected to create lucrative opportunities for the market.

Segmental Outlook

The global biomarker market is segmented based on type, application, disease, and end-user. On the basis of type, the market is bifurcated into genomic and protein biomarker. The application segment is classified into drug discovery & development, diagnostic, prognostic, predictive and others (risk assessment). Among these, the biomarkers in drug discovery and development are anticipated to grow at significant CAGR during the forecast period. Biomarkers can predict the drug efficacy more quickly than conventional clinical endpoints, also they have the potential to accelerate product development in certain disease areas such as cancer, and cardiac disease. The disease segment is segregated into cancer, cardiac, renal, central nervous system disease and others (NASH). The end-user segment is categorized into hospitals, diagnostic center and research institute.

Global Biomarker Market Share by Disease, 2020 (%)

Global Biomarker Market Share by Disease

The Cancer disease segment holds the Major Market Share in the global Biomarker Market

Among disease, the biomarker in cancer dominated the market in 2020, and it is anticipated to maintain its dominance during the forecast period. Due to rise in prevalence of cancer cases across the globe, the demand for cancer biomarker has increased significantly in recent years, that has positively impacted the market growth. According to estimates from the International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths simply due to the growth and ageing of the population. According to the WHO data for cancer 2020, cancer is the main cause of death across the globe. There were 10 million deaths accounted for due to various types of cancer such as lung (1.80 million), colon and rectum (935 000), liver (8,30,000), stomach (769 000), and breast (685 000 deaths). In cancer research and drug discovery, biomarkers are used in three ways such as diagnostic (support to diagnose the condition in early-stage), prognostic (to forecast how aggressive a condition is), and predictive (to predict the response after treatment). The rising prevalence of cancer disease will increase the use of biomarkers in research-related activities which will further expected to drive the market growth.

Regional Outlook

Geographically, the global Biomarker market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia-Pacific is the fastest-growing region during the forecast period. The factors contributing to the regional growth include the strong population base, high prevalence of chronic diseases such as cancer and CVDs in countries such as China, Japan, and India. Apart from this, improving biopharmaceutical research centers and rising clinical research in the region.

Global Biomarker Market Growth, by Region 2021-2027

Global Biomarker Market Growth, by Region

North America is projected to Dominate the Biomarker Market

Geographically, North America held the major market share in 2020, and it is anticipated to dominate the market during the forecast period. Major economies which contribute to the market are the US and Canada. Factors that are contributing significantly to the market growth include the presence of well-developed healthcare infrastructure, increasing healthcare R&D investments, high healthcare expenditure and others. The rising number of cancer patients is considered to be one of the major factors that are driving the growth of the market in the North American region. The healthcare expenditure rate of the US is more than that of Canada, as the US government invests more in R&D. Furthermore, socioeconomic factors such as health, income, population base creates more business opportunity in the US as compared to Canada.

Market Players Outlook

The key players in the biomarker market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Abbott Laboratories, Bio-Rad Laboratories Inc, Enzo Biochem Inc., EKF Diagnostics Holdings plc, PerkinElmer Inc, QIAGEN GmbH, Cisbio Bioassays, Johnson & Johnson Services, Inc., among others. To survive in the market, these market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions so on. For instance, in December 2020, Personalis, Inc. announced the launch of proprietary Neoantigen Presentation Score (NEOPS). It is a neoantigen-based composite biomarker for cancer immunotherapy response. NEOPS combines the tumor genomic and immune-related analytics of the Personalis, Next Platform in order to create a composite biomarker through which immunotherapy response can be predicted more effectively.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global biomarker market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Biomarker Industry
  • Recovery Scenario of Global Biomarker Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Biomarker Market, By Type
    • 5.1.1. Genomic Biomarker
    • 5.1.2. Protein Biomarker
  • 5.2. Global Biomarker Market, By Application
    • 5.2.1. Drug Discovery and Development
    • 5.2.2. Diagnostic
    • 5.2.3. Prognostic
    • 5.2.4. Predictive
    • 5.2.5. Others (Risk Assessment)
  • 5.3. Global Biomarker Market, By Disease
    • 5.3.1. Cancer
    • 5.3.2. Cardiac
    • 5.3.3. Renal
    • 5.3.4. Central Nervous System Disease
    • 5.3.5. Others (Nash)
  • 5.4. Global Biomarker Market, By End User
    • 5.4.1. Hospitals
    • 5.4.2. Diagnostic Centre
    • 5.4.3. Research Institute

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Russia
    • 6.2.7. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East Africa

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. ACS Biomarker B.V.
  • 7.3. Agilent technologies inc.
  • 7.4. Abcodia Ltd.
  • 7.5. Adx Neurosciences
  • 7.6. Avacta Life Sciences Ltd.
  • 7.7. Agendia Inc.
  • 7.8. Astellas Pharma Inc.
  • 7.9. Angle plc
  • 7.10. Almac Group

LIST OF TABLES

  • 1. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 2. GLOBAL GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL PROTEIN BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 5. GLOBAL BIOMARKER FOR DRUG DISCOVERY AND DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 6. GLOBAL BIOMARKER FOR DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 7. GLOBAL BIOMARKER FOR PROGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL BIOMARKER FOR PREDICTIVE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL BIOMARKER FOR OTHERS (RISK ASSESSMENT)MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE 2020-2027($ MILLION)
  • 11. GLOBAL BIOMARKER IN CANCER DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 12. GLOBAL BIOMARKER IN CARDIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 13. GLOBAL BIOMARKER IN RENAL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 14. GLOBAL BIOMARKER IN CENTRAL NERVOUS SYSTEM DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL BIOMARKER IN OTHERS(NASH) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 16. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER 2020-2027($ MILLION)
  • 17. GLOBAL BIOMARKER IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 18. GLOBAL BIOMARKER IN DIAGNOSTIC CENTRE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 19. GLOBAL BIOMARKER IN RESEARCH INSTITUTE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 20. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027($ MILLION)
  • 21. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 22. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 23. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION,2020-2027($ MILLION)
  • 24. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE 2020-2027($ MILLION)
  • 25. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER 2020-2027($ MILLION)
  • 26. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 27. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 28. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 29. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027($ MILLION)
  • 30. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 31. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 32. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 33. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 34. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027($ MILLION)
  • 35. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 36. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 37. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 38. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 39. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027($ MILLION)
  • 40. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER , 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 2. GLOBAL GENOMIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL PROTEIN BIOMARKER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 5. GLOBAL BIOMARKER FOR DRUG DISCOVERY AND DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 6. GLOBAL BIOMARKER FOR DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 7. GLOBAL BIOMARKER FOR PROGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL BIOMARKER FOR PREDICTIVE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL BIOMARKER FOR OTHERS (RISK ASSESSMENT)MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE 2020-2027($ MILLION)
  • 11. GLOBAL BIOMARKER IN CANCER DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 12. GLOBAL BIOMARKER IN CARDIAC DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 13. GLOBAL BIOMARKER IN RENAL DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 14. GLOBAL BIOMARKER IN CENTRAL NERVOUS SYSTEM DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL BIOMARKER IN OTHERS(NASH) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 16. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER 2020-2027($ MILLION)
  • 17. GLOBAL BIOMARKER IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 18. GLOBAL BIOMARKER IN DIAGNOSTIC CENTRE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 19. GLOBAL BIOMARKER IN RESEARCH INSTITUTE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 20. GLOBAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027($ MILLION)
  • 21. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 22. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 23. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION,2020-2027($ MILLION)
  • 24. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE 2020-2027($ MILLION)
  • 25. NORTH AMERICAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER 2020-2027($ MILLION)
  • 26. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 27. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 28. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 29. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027($ MILLION)
  • 30. EUROPEAN BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 31. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 32. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 33. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 34. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027($ MILLION)
  • 35. ASIA-PACIFIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 36. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 37. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
  • 38. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027($ MILLION)
  • 39. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027($ MILLION)
  • 40. REST OF THE WORLD BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER , 2020-2027($ MILLION)